A RevCycleIntelligence article entitled “CMS Targets Value-Based Purchasing, Drug Costs to Reduce Spending” references the Leavitt Partners “Accountable Care Organizations and Risk-Based Payment Arrangements: Strong Preference for Upside-Only Contracts” white paper. The article states, “About 61 percent of ACO contracts contain only upside financial risk, meaning organizations do not have to repay financial losses, a … Read more
CMS’s recent integration of health equity into its new and existing value-based payment (VBP) programs (as outlined below) signals a strong commitment to equitable care delivery. We expect health equity to be incorporated into additional federal programs and for private payers to follow CMS’s example in designing their own plans for managing the diverse needs … Read more
Leavitt Partners examined publicly available resources to determine the 340B Drug Pricing Program’s (340B) impact on drug prices charged by both covered entities and pharmaceutical manufacturers. To answer these questions, Leavitt Partners undertook a comprehensive literature review of publicly available governmental reports, peer-reviewed journal articles, white papers, news articles, and other publicly available sources to … Read more
Today, Health Management Associates (HMA) launched the Leavitt Center for Alliances, an HMA Initiative, which aims to elevate the national discourse on healthcare and help healthcare organizations solve their most complex challenges through consensus-based alliances. The Leavitt Center for Alliances (Leavitt Center) is home to expert conveners who have decades of experience in the private … Read more
Consumer health app developers are finding ways to help consumers and their physicians make better use of their health data. These apps can now get accredited for their compliance with best practices in managing personal health information, an important step towards building trust that consumers’ health data will be protected as it is moved more … Read more
Nonadherence to a prescribed medication regimen for patients with chronic pain is associated with overall lower health outcomes, including increased hospital admissions, costs, and morbidity (quantitative review here). Deviations in timing, dosage, frequency, or duration of medication—all components of noncompliance—can cause medical reactions, increased pain, and medication use disorders, and can ultimately lead to emergency care … Read more
In April 2022, we published a blog post exploring Q1 digital health funding within the US using a framework introduced by Leavitt Partners in a recently published whitepaper. Applying the same methods, we tracked funding across the digital health landscape In Q2. Q2 saw 144 deals in digital health for a total investment of $4.6 billion and an average deal … Read more
Partnership Calls on Policymakers to Implement Proposals in 2020 Landmark Report Washington, D.C. — In recognition of World Sickle Cell Day on June 19th, today more than a dozen organizations representing a diverse cross-section of patient advocates, health professional organizations, health insurers and biopharmaceutical companies announced the launch of the Sickle Cell Disease Partnership. The … Read more
The COVID-19 pandemic significantly accelerated the demand for digital healthcare alternatives. As a result, private investors are looking for promising digital health startups or companies to financially back. One common problem investors will undoubtedly encounter when assessing opportunities in digital health is that stakeholders are often not speaking the same language. In February 2022, Leavitt Partners … Read more
As respiratory syncytial virus (RSV), a seasonal pathogen in young children is challenging the national health care system as part of an unprecedented “tripledemic” with COVID-19 and flu this winter, authors with Leavitt Partners parent company Health Management Associates weigh in on potential coverage pathways for new monoclonal antibody (mAb) preventive therapies for RSV and … Read more
